Velesco acquires facility, triples clinical manufacturing capacity

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/ittayayut)
(Image: Getty/ittayayut)

Related tags: Velesco, Contract manufacturing, Contract manufacturing organisation, CDMO

Velesco to triple its capacity for non-sterile clinical material manufacturing and consolidate its cGMP capabilities with the purchase of a facility in Wixom, Michigan.

Michigan, US-based contract development and manufacturing organisation (CDMO), Velesco Pharma, announced the purchase of a facility which will triple the company’s manufacturing capacity.

The building added to Velesco’s assets features a processing suite space, which is expected to allow Velesco to provide enhanced current good manufacturing practice (cGMP) capabilities.

A spokesperson for Velesco also told us that the building, which was previously owned by a constructions company, will include a warehouse and a materials management area, and will manufacture oral liquids, semi-solids and solid dose products used in early phase clinical trials. 

The facility will be supported by the company’s existing quality check release and stability testing laboratory, also located in Wixom, while the company also plans to consolidate its manufacturing site in Kalamazoo, MI.

Dave Barnes, Velesco’s CEO, commented on the purchase, stating that it will enable the company to meet growing client demands, “while still maintaining our science-focus and flexible approach to client projects.”

The new facility is set to be fully operational by the end of this year.

Steady expansion steps

Formed in 2007 by former Pfizer Michigan Research and Development (Pharmaceutical Science) colleagues, Velesco has been making steady steps building on its expansion during the past years.

In late 2018​, the company announced a doubling of its analytical research and development capabilities with the acquisition of a building near its facility in Wixom, concurrently announcing an increase of its scientific team.

The company’s CEO told us then that this move answered increased market demands and that it would allow sponsors to advance new medicines into the clinic faster.

The expansion followed the addition of compound management services to the company’s portfolio, aiming to meet increased demand for materials management, in 2016​.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars